Page 1

H XENON Xenon Pharmaceuticals Announces Completion of Patient Randomization in XEN1101 Phase 2b " X - TOLE " Clinical Trial and Announces Upcoming Investor Webinar with Leading Epilepsy Key Opinion Leaders July 7 , 2021 Webinar to be broadcast live on Monday , July 12 , 2021 beginning at 10 am ET BURNABY , British Columbia , July 07 , 2021 ( GLOBE NEWSWIRE ) Xenon Pharmaceuticals Inc. ( Nasdaq : XENE ) , a neurology - focused biopharmaceutical company , today provided an update on its ongoing XEN1101 Phase 2b " X - TOLE ” clinical trial , announcing that randomization of 326 patients was completed in late June . Based on completion of patient randomization , Xenon anticipates topline results from the Phase 2b X - TOLE clinical trial in late September to mid - October 2021 . Mr. Ian Mortimer , Xenon's President and Chief Executive Officer , said , " We are pleased to announce that patient randomization in our XEN1101 Phase 2b " X - TOLE " clinical trial is complete . Given the strong screening at the end of the recruitment period , we randomized more patients than the 300 originally planned , and we look forward to topline data in late September to mid - October . In advance of these results , we have invited two leading key opinion leaders in the epilepsy space - Dr. Jacqueline French and Dr. Michael Rogawski - to join us for a webinar to discuss XEN1101 , the X - TOLE clinical trial , and the broader focal epilepsy landscape . " Webinar Event : " A Discussion of XEN1101 and the Focal Epilepsy Landscape " Date : Time : Monday , July 12 , 2021 10 am - 12 pm Eastern Time ( 7 am - 9 am Pacific Time ) Registration : Participants may register on the Investors section of Xenon's website . Speakers on the July 12th webinar include : • Dr. Jacqueline French , Professor of Neurology in the Comprehensive Epilepsy Center at NYU Langone School of Medicine and Founder / Director of the Epilepsy Study Consortium • Dr. Michael Rogawski , Professor in the Department of Neurology with joint appointment in the Department of Pharmacology , and an affiliate member of the Center for Neuroscience at the University of California , Davis • lan Mortimer , President and CEO , Xenon Pharmaceuticals • Dr. Simon Pimstone , Executive Chair of the Board , Xenon Pharmaceuticals Dr. Chris Von Seggern , Chief Commercial Officer , Xenon Pharmaceuticals